Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

GILD

Gilead Sciences, Inc.

Jun 14 • 04:00PM ET

65.06

Dollar change +1.50
Percentage change 2.36	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ SPY IVV VTV XLV IBB COWZ VYM

Scroll to Statements

Index	NDX, S&P 500	P/E	181.38	EPS (ttm)	0.36	Insider Own	0.09%	Shs Outstand	1.25B	Perf Week	0.56%
Market Cap	81.05B	Forward P/E	9.06	EPS next Y	7.18	Insider Trans	-2.22%	Shs Float	1.24B	Perf Month	-2.91%
Income	484.00M	PEG	33.68	EPS next Q	1.59	Inst Own	85.66%	Short Float	2.04%	Perf Quarter	-11.71%
Sales	27.42B	P/S	2.96	EPS this Y	-43.83%	Inst Trans	0.85%	Short Ratio	3.63	Perf Half Y	-21.70%
Book/sh	14.08	P/B	4.62	EPS next Y	90.27%	ROA	0.82%	Short Interest	25.43M	Perf Year	-16.54%
Cash/sh	4.86	P/C	13.38	EPS next 5Y	5.38%	ROE	2.51%	52W Range	62.07 - 87.86	Perf YTD	-19.69%
Dividend Est.	3.10 (4.77%)	P/FCF	10.26	EPS past 5Y	1.55%	ROI	1.24%	52W High	-25.95%	Beta	0.19
Dividend TTM	3.79 (5.83%)	Quick Ratio	0.94	Sales past 5Y	4.16%	Gross Margin	77.68%	52W Low	4.82%	ATR (14)	1.33
Dividend Ex-Date	Jun 14, 2024	Current Ratio	1.08	EPS Y/Y TTM	-91.37%	Oper. Margin	34.04%	RSI (14)	48.67	Volatility	2.15% 1.97%
Employees	18000	Debt/Eq	1.44	Sales Y/Y TTM	2.13%	Profit Margin	1.77%	Recom	2.16	Target Price	82.17
Option/Short	Yes / Yes	LT Debt/Eq	1.23	EPS Q/Q	-517.48%	Payout	66.62%	Rel Volume	1.28	Prev Close	63.56
Sales Surprise	5.17%	EPS Surprise	11.60%	Sales Q/Q	5.66%	Earnings	Apr 25 AMC	Avg Volume	7.01M	Price	65.06
SMA20	-0.24%	SMA50	-1.71%	SMA200	-12.47%	Trades		Volume	9,003,971	Change	2.36%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87
Dec-13-22	Resumed	BofA Securities	Neutral	$85
Dec-09-22	Downgrade	DZ Bank	Buy → Hold	$90
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight	$60 → $76
Oct-28-22	Upgrade	Truist	Hold → Buy	$76 → $91
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight	$79 → $96
Oct-28-22	Reiterated	Wells Fargo	Equal Weight	$74 → $75
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform	$79 → $82
Oct-28-22	Reiterated	JP Morgan	Overweight	$80 → $87
Oct-28-22	Reiterated	Jefferies	Buy	$78 → $86
Oct-28-22	Reiterated	Cowen	Outperform	$75 → $80

Show Previous Ratings

Jun-14-24 04:19PM	Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar (Investor's Business Daily)
02:27PM	Gilead Stock Gains. Its Trying to Get Into the Obesity Drug Game. (Barrons.com)
07:01AM	Gilead Sciences Inc's Dividend Analysis (GuruFocus.com)
03:00AM	New Kite Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit From Earlier Lines of Treatment (Business Wire)
Jun-13-24 06:00PM	Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts (Zacks)
09:00AM	Loading…
Jun-12-24 09:00AM	How Luciana Preger Is Helping Advance Gilead's Work in Oncology (ACCESSWIRE)
Jun-08-24 06:50AM	3 Stocks With Mouthwatering Dividends You Can Buy Right Now (Motley Fool)
Jun-07-24 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know (Zacks)
11:36AM	The City With the highest HIV/AIDS Rates in the US (Insider Monkey)
11:35AM	20 Cities With the Highest HIV/AIDS Rates in the US (Insider Monkey)
Jun-06-24 09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
04:45AM	Gileads seladelpar shows promise in primary biliary cholangitis trial (Clinical Trials Arena)
04:30AM	Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA (Business Wire)
Jun-05-24 09:45AM	Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100? (Motley Fool)
09:15AM	Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis (ACCESSWIRE)
07:55AM	Loading…
07:55AM	Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks (BioPharma Dive)
07:00AM	The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream (InvestorPlace)
06:40AM	7 Dividend Stocks to Invest In for a Lifetime of Income (InvestorPlace)
05:06AM	Gilead progresses subject enrolment in HIV prevention trials (Clinical Trials Arena)
04:25AM	J&J seeks expanded approvals for paediatric HIV-1 therapy (Pharmaceutical Technology)
02:00AM	Gileads Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis (Business Wire)
Jun-04-24 03:57PM	National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection (Benzinga)
06:15AM	3 Dividend Stocks That Even Ken Griffin Is Buying (InvestorPlace)
Jun-03-24 04:26PM	Hedge Funds are Bullish on This Gene Therapy Stock (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
01:59PM	Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study (Zacks)
10:00AM	Kites Tecartus Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (Business Wire)
09:00AM	Encouraging New Data Presented on Kites Yescarta for Relapsed/Refractory Central Nervous System Lymphoma (Business Wire)
Jun-02-24 08:00AM	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer (Business Wire)
Jun-01-24 08:00AM	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers (Business Wire)
01:01PM	Loading…
May-31-24 01:01PM	Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal (Zacks)
12:18PM	15 Most Profitable Biotechnology Companies in the World (Insider Monkey)
08:07AM	EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 (Business Wire)
07:01AM	Gileads Trodelvy misses goal in bladder cancer study (BioPharma Dive)
04:25AM	Gileads Phase III urothelial cancer trial fails to meet primary endpoint (Clinical Trials Arena)
May-30-24 04:45PM	Gilead Provides Update on Phase 3 TROPiCS-04 Study (Business Wire)
May-29-24 02:02PM	Buy Low, Hold Long: 2 Crushed Dividend Stocks To Buy For High Yields And Long-Term Gains (Benzinga)
06:05AM	Gilead and Cartography enter deal to develop cancer therapies (Pharmaceutical Technology)
May-28-24 09:50AM	Gilead Sciences Partners With White House for Early Cancer Detection Program 'Biden Cancer Moonshot' (ACCESSWIRE)
09:45AM	2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years (Motley Fool)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-22-24 05:17PM	Top 20 Largest Publicly Traded Healthcare Companies (Insider Monkey)
10:48AM	3 Biotech Stocks to Buy Now: May 2024 (InvestorPlace)
08:30AM	Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 (Business Wire)
May-21-24 10:15AM	Gilead Sciences Hosts Inaugural Global Health Equity Summit (ACCESSWIRE)
09:00AM	Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock (Zacks)
May-20-24 11:36AM	Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch (Benzinga)
10:43AM	Gilead (GILD) Announces Positive Interim Results on PBC Drug (Zacks)
May-18-24 08:30AM	Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis (Business Wire)
08:06AM	Flora Growth Corp. (NASDAQ:FLGC) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-16-24 02:27PM	Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch (InvestorPlace)
May-14-24 10:09AM	Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy (Business Wire)
08:45AM	Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care (ACCESSWIRE)
May-13-24 12:41PM	One stock is dragging down the S&P 500's earnings growth (Yahoo Finance)
May-10-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
May-09-24 04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
09:45AM	Gilead's FOCUS Program Helps Zero In on Early HIV Detection (ACCESSWIRE)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
01:07AM	Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight (GuruFocus.com)
May-07-24 09:45AM	Gilead Helps Put African Nation on Path To Eliminate Hepatitis C (ACCESSWIRE)
08:30AM	Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024 (Business Wire)
May-06-24 12:39PM	Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back (InvestorPlace)
May-04-24 07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
May-03-24 08:11PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
02:00PM	Forbes Has Listed Gilead as One of America's Best Employers for Diversity (ACCESSWIRE)
May-02-24 11:29AM	UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating (MT Newswires)
May-01-24 02:38PM	Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar (InvestorPlace)
10:53AM	Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 (MT Newswires)
10:19AM	Maxim Adjusts Price Target on Gilead Sciences to $85 From $90 (MT Newswires)
08:25AM	Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120 (MT Newswires)
Apr-30-24 04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences (Business Wire)
12:01PM	Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-29-24 09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:18AM	Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 (MT Newswires)
06:01AM	Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data (Clinical Trials Arena)
Apr-28-24 05:50PM	American Politicians are Selling These 10 Stocks (Insider Monkey)
Apr-26-24 04:31PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
04:10PM	Gilead Gives Up Big Gains As Covid Drug Drives Its Beat Again (Investor's Business Daily)
11:44AM	3 Dividend Stocks to Buy at a 52-Week Low in April (InvestorPlace)
10:45AM	TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 (MT Newswires)
10:24AM	Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat (Zacks)
10:09AM	Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 (MT Newswires)
10:08AM	RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76 (MT Newswires)
09:59AM	Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80 (MT Newswires)
09:14AM	Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy (MT Newswires)
08:11AM	Q1 2024 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	FDA Approves Biktarvy Label Update With Data for Pregnant Adults With HIV (Business Wire)
03:35AM	Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ... (GuruFocus.com)
Apr-25-24 09:45PM	Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:49PM	Gilead Beats Earnings Expectations After Rocky Quarter (Barrons.com)
05:41PM	Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ... (GuruFocus.com)
05:15PM	Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:59PM	UPDATE 1-Gilead posts quarterly loss on acquisition charge, revenue rises 5% (Reuters)
04:50PM	Gilead Sciences Q1 Tops Estimates, Updates Outlook (MT Newswires)
04:40PM	Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again (Investor's Business Daily)
04:14PM	Gilead: Q1 Earnings Snapshot (Associated Press Finance)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706	Feb 29 06:35 PM
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936	Feb 29 06:35 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124	Jan 31 05:00 PM
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534	Jan 17 06:01 PM
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729	Jan 10 03:58 PM
Dickinson Andrew D	Chief Financial Officer	Oct 17 '23	Sale	80.00	5,000	400,017	104,003	Oct 18 04:31 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '23	Sale	76.99	1,501	115,562	70,130	Sep 13 06:50 PM
Dickinson Andrew D	Chief Financial Officer	Jul 20 '23	Sale	80.00	5,000	400,000	107,587	Jul 21 05:30 PM
GILEAD SCIENCES, INC.	10% Owner	Jun 28 '23	Buy	19.26	1,010,000	19,452,600	14,823,029	Jun 30 03:12 PM
GILEAD SCIENCES, INC.	10% Owner	Jun 27 '23	Buy	3.75	2,930,870	10,990,762	16,635,286	Jun 28 05:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc.

Upgrade your FINVIZ experience